<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="study presents a perfect model for COVID-19 RdRp enabling its" exact="testing" post="in silico against anti-polymerase drugs. Besides, the study presents"/>
 <result pre="WHO distributed interim guidance for laboratories that carry out the" exact="testing" post="for the newly emerged outbreak and infection prevention and"/>
 <result pre="carry out the testing for the newly emerged outbreak and" exact="infection" post="prevention and control guidance [4,5]. COVID-19 viral pneumonia is"/>
 <result pre="number of attempts to develop anti-RdRp compounds are under clinical" exact="testing" post="against different viruses. The half-maximal Effective Concentration (EC50) for"/>
 <result pre="outbreak in the Middle East region has an entirely different" exact="infection" post="pattern (MERS) leaving &amp;gt;800 deaths and 2500 hospitalizations. The"/>
 <result pre="possible inhibitors, DAA drugs, currently in the market stop the" exact="infection" post="immediately. Sofosbuvir, Ribavirin, and Remdisivir can be used against"/>
 <result pre="plus ribavirin compared with interferon alfa-2b plus ribavirin for initial" exact="treatment" post="of chronic hepatitis C: a randomised trialLancet358200195896511583749 57WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.Therapeutic efficacy"/>
</results>
